Literature DB >> 10695472

Arrhythmias in heart failure: current concepts of mechanisms and therapy.

L Eckardt1, W Haverkamp, R Johna, D Böcker, M C Deng, G Breithardt, M Borggrefe.   

Abstract

About one half of deaths in patients with heart failure are sudden, mostly due to ventricular tachycardia (VT) degenerating to ventricular fibrillation or immediate ventricular fibrillation. In severe heart failure, sudden cardiac death also may occur due to bradyarrhythmias. Other dysrhythmias complicating heart failure include atrial and ventricular extrasystoles, atrial fibrillation (AF), and sustained and nonsustained ventricular tachyarrhythmias. The exact mechanism of the increased vulnerability to arrhythmias is not known. Depending on the etiology of heart failure, different preconditions, including ischemia or structural alterations such as fibrosis or myocardial scarring, may be prominent. Reentrant mechanisms around scar tissue, afterdepolarizations, and triggered activity due to changes in calcium metabolism significantly contribute to arrhythmogenesis. Furthermore, alterations in potassium currents leading to action potential prolongation and an increase in dispersion of repolarization play a significant role. Treatment of arrhythmias is necessary either because patients are symptomatic or to reduce the risk for sudden cardiac death. The individual history, left ventricular function, electrophysiologic testing, and the signal-averaged ECG give useful information for identifying patients at risk for sudden cardiac death. The implantable cardioverter defibrillator (ICD) has evolved as a promising therapy for life-threatening arrhythmias. A potential role may exist for antiarrhythmic drugs, mainly amiodarone. There is growing evidence that patients with sustained VT or a history of resuscitation have the best outcome with ICD therapy regardless of the degree of heart failure. Many of these patients require additional antiarrhythmic therapy because of AF or nonsustained VTs that may activate the device. Catheter ablation or map-guided endocardial resection are additional options in selected patients but seldom represent the only therapeutic strategy.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10695472     DOI: 10.1111/j.1540-8167.2000.tb00746.x

Source DB:  PubMed          Journal:  J Cardiovasc Electrophysiol        ISSN: 1045-3873


  10 in total

Review 1.  Use of stem cells in heart failure treatment: where we stand and where we are going.

Authors:  Luis A Sánchez; Carlos Enrique Guerrero-Beltrán; Andrea M Cordero-Reyes; Gerardo García-Rivas; Guillermo Torre-Amione
Journal:  Methodist Debakey Cardiovasc J       Date:  2013 Oct-Dec

2.  Blockade of I(Ca) suppresses early afterdepolarizations and reduces transmural dispersion of repolarization in a whole heart model of chronic heart failure.

Authors:  P Milberg; M Fink; C Pott; G Frommeyer; J Biertz; N Osada; J Stypmann; G Mönnig; M Koopmann; G Breithardt; L Eckardt
Journal:  Br J Pharmacol       Date:  2012-05       Impact factor: 8.739

3.  The use of Bcl-2 over-expression to stabilize hybridomas specific to the HERG potassium channel.

Authors:  Jakub Sroubek; Yamini Krishnan; Jordan Chinai; Susan Buhl; Matthew D Scharff; Thomas V McDonald
Journal:  J Immunol Methods       Date:  2011-11-15       Impact factor: 2.303

4.  Survival benefit of primary prevention implantable cardioverter-defibrillator therapy after myocardial infarction: does time to implant matter? A meta-analysis using patient-level data from 4 clinical trials.

Authors:  Paul L Hess; Amy Laird; Rex Edwards; Gust H Bardy; J Thomas Bigger; Alfred E Buxton; Arthur J Moss; Kerry L Lee; W J Hall; Richard Steinman; Paul Dorian; Al Hallstrom; Riccardo Cappato; Alan H Kadish; Peter J Kudenchuk; Daniel B Mark; Sana M Al-Khatib; Jonathan P Piccini; Lurdes Y T Inoue; Gillian D Sanders
Journal:  Heart Rhythm       Date:  2013-02-13       Impact factor: 6.343

5.  Cardiac Arrhythmia: In vivo screening in the zebrafish to overcome complexity in drug discovery.

Authors:  Calum A Macrae
Journal:  Expert Opin Drug Discov       Date:  2010-07       Impact factor: 6.098

6.  Protein kinase A activity at the endoplasmic reticulum surface is responsible for augmentation of human ether-a-go-go-related gene product (HERG).

Authors:  Jakub Sroubek; Thomas V McDonald
Journal:  J Biol Chem       Date:  2011-05-02       Impact factor: 5.157

Review 7.  Drug-induced proarrhythmia: risk factors and electrophysiological mechanisms.

Authors:  Gerrit Frommeyer; Lars Eckardt
Journal:  Nat Rev Cardiol       Date:  2015-07-21       Impact factor: 32.419

Review 8.  Calcium handling and ventricular tachyarrhythmias.

Authors:  Gerrit Frommeyer; Lars Eckardt; Peter Milberg
Journal:  Wien Med Wochenschr       Date:  2012-06-07

9.  Inflammatory biomarkers are not predictive of intermediate-term risk of ventricular tachyarrhythmias in stable CHF patients.

Authors:  Yuval Konstantino; Jairo Kusniec; Tamar Reshef; Ofer David-Zadeh; Alexander Mazur; Boris Strasberg; Alexander Battler; Moti Haim
Journal:  Clin Cardiol       Date:  2007-08       Impact factor: 2.882

Review 10.  Using Zebrafish for High-Throughput Screening of Novel Cardiovascular Drugs.

Authors:  Aaron Kithcart; Calum A MacRae
Journal:  JACC Basic Transl Sci       Date:  2017-02-27
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.